Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
compound lactobacillus (Gansu Provincial Hospital of Traditional Chinese Medicine)
- Development stage
- Unknown
- Lead developer
- Gansu Provincial Hospital of Traditional Chinese Medicine
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Compound lactobacillus is a multi-strain probiotic preparation typically composed of live bacteria including *Lactobacillus acidophilus*, *Lactobacillus bulgaricus*, and *Streptococcus thermophilus*. It is primarily used to regulate intestinal microecology by restoring the balance of commensal flora, inhibiting the growth of pathogenic bacteria, and enhancing the intestinal mucosal barrier. In clinical research, particularly in China, it is investigated for its role in managing systemic inflammatory conditions such as sepsis-related acute respiratory distress syndrome (ARDS). The therapeutic rationale involves modulating the gut-lung axis to reduce bacterial translocation and systemic cytokine release, which are key drivers of lung injury in septic patients.
- Brand names
- Wan Tuo
- Other names
- Compound Lactobacillus CapsulesFuhe Rusuanjun
02
Targets
NOD1 (Nucleotide-binding oligomerization domain-containing protein 1)TLR2/TLR6 (Toll-like receptor 2/Toll-like receptor 6 pattern recognition receptor complex)msGPCRs (Metabolite-sensing G protein-coupled receptors)
Beyond the preview
Go deeper on compound lactobacillus (Gansu Provincial Hospital of Traditional Chinese Medicine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on compound lactobacillus (Gansu Provincial Hospital of Traditional Chinese Medicine).